Zacks Research Has Pessimistic Outlook of ORMP Q3 Earnings

Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) – Stock analysts at Zacks Research decreased their Q3 2026 earnings per share (EPS) estimates for Oramed Pharmaceuticals in a research note issued on Friday, August 28th. Zacks Research analyst M. Marin now expects that the biotechnology company will earn $0.43 per share for the quarter, down from their prior forecast of $0.52. The consensus estimate for Oramed Pharmaceuticals’ current full-year earnings is $1.24 per share. Zacks Research also issued estimates for Oramed Pharmaceuticals’ Q4 2026 earnings at $0.37 EPS and FY2026 earnings at $3.40 EPS.

Several other equities analysts also recently issued reports on the stock. Wall Street Zen raised shares of Oramed Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Saturday, August 15th. Weiss Ratings raised shares of Oramed Pharmaceuticals from a “hold (c)” rating to a “hold (c+)” rating in a research note on Thursday, June 11th. One investment analyst has rated the stock with a Hold rating, According to MarketBeat.com, the company has an average rating of “Hold”.

Oramed Pharmaceuticals Stock Performance

ORMP opened at $4.85 on Wednesday. The firm’s 50-day simple moving average is $4.44 and its 200-day simple moving average is $3.97. Oramed Pharmaceuticals has a twelve month low of $2.09 and a twelve month high of $5.47. The firm has a market cap of $201.75 million, a price-to-earnings ratio of 1.18 and a beta of 1.22.

Oramed Pharmaceuticals (NASDAQ:ORMP) last issued its quarterly earnings data on Monday, August 10th. The biotechnology company reported ($0.09) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.43 by ($0.52).

Insiders Place Their Bets

In other Oramed Pharmaceuticals news, CFO Avraham Gabay sold 73,360 shares of the business’s stock in a transaction on Wednesday, July 1st. The stock was sold at an average price of $4.51, for a total value of $330,853.60. Following the transaction, the chief financial officer owned 671,785 shares of the company’s stock, valued at approximately $3,029,750.35. The trade was a 9.85% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, COO Joshua Hexter sold 137,000 shares of the firm’s stock in a transaction on Wednesday, July 1st. The shares were sold at an average price of $4.46, for a total value of $611,020.00. Following the completion of the sale, the chief operating officer owned 1,023,384 shares of the company’s stock, valued at approximately $4,564,292.64. This trade represents a 11.81% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 20.77% of the stock is currently owned by insiders.

Institutional Trading of Oramed Pharmaceuticals

A number of hedge funds have recently modified their holdings of the company. Bank of New York Mellon Corp acquired a new position in Oramed Pharmaceuticals during the second quarter valued at approximately $381,000. Bank of America Corp DE grew its holdings in shares of Oramed Pharmaceuticals by 2.7% in the 1st quarter. Bank of America Corp DE now owns 146,152 shares of the biotechnology company’s stock valued at $497,000 after buying an additional 3,909 shares during the period. OMERS ADMINISTRATION Corp acquired a new position in shares of Oramed Pharmaceuticals in the 1st quarter valued at $63,000. Dimensional Fund Advisors LP increased its position in shares of Oramed Pharmaceuticals by 5.1% in the 1st quarter. Dimensional Fund Advisors LP now owns 158,209 shares of the biotechnology company’s stock valued at $538,000 after buying an additional 7,738 shares in the last quarter. Finally, Hillsdale Investment Management Inc. bought a new stake in shares of Oramed Pharmaceuticals in the 1st quarter valued at $331,000. 12.73% of the stock is currently owned by institutional investors and hedge funds.

About Oramed Pharmaceuticals

Oramed Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of proprietary oral drug delivery systems, with an initial emphasis on diabetes management. Headquartered in Jerusalem, Israel, the company leverages its patented protein encapsulation technology, the “Oral Delivery Platform,” to transform injectable therapies into patient-friendly oral formulations. Oramed’s platform is designed to protect sensitive proteins and peptides from degradation in the gastrointestinal tract, enabling successful absorption and systemic delivery.

The company’s lead candidate, ORMD-0801, is an oral insulin capsule for patients with type 2 diabetes, currently advancing through Phase 3 clinical trials.